DIFFERENTIATION OF IMMATURE T CELL NEOPLASMS BY INTERLEUKIN-2

我们对45例T细胞和髓系白血病进行了研究，试图 进一步描述它们的特征。在15个案例中，这些细胞对 使用IL-2治疗，因为它们具有杀死肿瘤的能力 细胞。它们的表型变化类似于更多的 成熟的T细胞。利用这些案例，我们研究了 T细胞受体在生成细胞毒活性中的作用。在一个案例中， IL-2利用TCRγ增量诱导细胞增殖。 我们证明了这种TCR在抗CD3中起作用 刺激细胞内(Ca2+)升高并增强 MHC-不受限制的细胞分析。TCR伽马三角洲的三角关系 在这种情况下，直接导致细胞溶解颗粒酶的释放。 在研究IL-2在这一过程中的作用时，我们观察到 我们在IL-2之后记录的变化仅通过 P75 IL-2结合蛋白，而不是p55(TAC)蛋白。基于 这些发现，我们已经开始了一项临床方案，合作 和DRS在一起。Pplack和Kirsh，研究rIL-2的有效性 作为治疗未成熟T细胞恶性肿瘤的体内药物。

We have studies 45 cases of T cell and myeloid leukemia trying to further characterize them. In 15 cases, these cells respond to treatment with IL-2, in that they develop the ability to kill tumor cells. Their phenotype changes to resemble that of a more mature T cell. Using these cases, we have studied the role of the T cell receptor in generation of cytotoxic activity. In one case, IL-2 induced a proliferation of cells utilizing TCR gamma delta. We demonstrated that this TCR was functional in that anti-CD3 stimulated an elevation of intracellular (CA2+) and augmented MHC-unrestricted cytalysis. Trigerring of the TCR gamma delta in this case leads directly to release of cytolytic granule enzymes. In studying the role of IL-2 in this process, we observed that the changes we recorded following IL-2 were transduced solely via the P75 IL-2 binding protein and not the P55 (TAC) protein. Based on these findings, we have begun a clinical protocol, in collaboration with DRS. Poplack and Kirsh, to study the effectiveness of rIL-2 in vivo as a treatment for immature T cell malignancies.